Cefpodoxime Proxetil 200 mg + Clavulanic Acid 125 mg Tablets
PROXINA-CL combines cefpodoxime proxetil, an oral third-generation cephalosporin antibiotic, with clavulanic acid, a beta-lactamase inhibitor.
Cefpodoxime acts by inhibiting bacterial cell-wall synthesis. Clavulanic acid inhibits certain beta-lactamase enzymes that can otherwise inactivate susceptible beta-lactam antibiotics.
The combination has been approved in India for selected respiratory tract, uncomplicated skin and urinary tract infections. Its use should be guided by clinical assessment, bacterial susceptibility and current antimicrobial treatment recommendations.
The addition of clavulanic acid does not overcome all mechanisms of bacterial resistance. Appropriate antibiotic selection remains essential.
Dosage Form: Tablets
Packing: 10 x 6 Strip Pack
Prescription medicine. To be used under the supervision of a registered medical practitioner.
Two-component antibacterial formulation: Combines cefpodoxime with clavulanic acid.
Cephalosporin action: Cefpodoxime inhibits bacterial cell-wall synthesis.
Beta-lactamase inhibition: Clavulanic acid inhibits certain bacterial beta-lactamase enzymes.
Complementary mechanisms: The components address bacterial cell-wall synthesis and selected beta-lactamase-mediated resistance mechanisms.
Clinical selection: Treatment should consider the likely pathogen, susceptibility findings, patient factors and relevant prescribing guidelines.
Therapeutic Indications
Upper Respiratory Tract Infections (URTI): Treatment of susceptible bacterial upper respiratory tract infections.
Lower Respiratory Tract Infections (LRTI): Treatment of susceptible bacterial lower respiratory tract infections.
Uncomplicated Skin Infections: Treatment of uncomplicated bacterial skin infections caused by susceptible organisms.
Urinary Tract Infections (UTI): Treatment of susceptible bacterial urinary tract infections.
Use should follow the approved product label, clinical assessment and local antimicrobial susceptibility patterns. Not intended for viral infections.
Verified product information, formulation specifications, and commercial supply pathways for registered healthcare professionals, institutions, and trade partners.
Review verified active composition, strength, dosage form, and packaging details on this page.
View SpecificationsRequest formulation literature, technical specifications, or product communication from our commercial team.
Submit Product EnquiryConnect regarding institutional supply requirements, trade distribution, or third-party contract manufacturing.
Commercial EnquiryThis product information is intended for registered healthcare professionals, medical practitioners, and authorized distribution partners. Product manufacturing is coordinated through eligible facility partners under applicable licences.
Request information about PROXINA-CL for professional use.